No Ticagrelor Clinical Gain vs Clopidogrel in PAD: EUCLID Top-line Results

Larry Hand

October 07, 2016

LONDON, UK — Ticagrelor (Brilinta, Brilique, AstraZeneca) did not demonstrate a clinical benefit over clopidogrel in the Examining Use of Ticagrelor in Peripheral Artery Disease (EUCLID) trial, according to top-line results announced by the company[1].

EUCLID included 13,885 patients in 28 countries—said to be the largest cardiovascular trial exclusively involving symptomatic patients with peripheral artery disease (PAD).

Researchers evaluated whether ticagrelor 90-mg tablets twice daily showed a benefit over clopidogrel 75 mg once daily in the prevention of cardiovascular death, heart attack, or stroke.

Ticagrelor did not meet the primary end point of time to first occurrence of cardiovascular death, MI, or ischemic stroke.

Full results of the EUCLID are scheduled to be presented in November at the American Heart Association 2016 Scientific Sessions in New Orleans.

Follow Larry Hand on Twitter: @LarryHand16. For more from, follow us on Twitter and Facebook.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.